DWA
MACK

Dorsey Wright & Associates’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Dorsey Wright & Associates’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,933
Closed -$23.8K – 307
2023
Q3 		$23.8K Sell
1,933
-67
-3% -$811 0.01% 212
2023
Q2 		$24.6K Buy
2,000
+201
+11% +$2.51K 0.01% 218
2023
Q1 		$22.1K Buy
+1,799
New +$21.1K 0.01% 211

Other funds holding MACK

WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dorsey Wright & Associates's MACK Position: Q4 2023 in Review

Dorsey Wright & Associates sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2023, closing a stake of 1,933 shares — an estimated $23.8K sold.

Dorsey Wright & Associates first reported a position in MACK in Q1 2023 and held it in 3 quarters. The position peaked at $24.6K in Q2 2023. 67 funds tracked by Wall St. Rank hold MACK as of Q4 2023.

  • Dorsey Wright & Associates reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,933 Merrimack Pharmaceuticals, Inc. shares in Q4 2023, an estimated $23.8K.
  • Dorsey Wright & Associates first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2023 and held it in 3 quarters.
  • Dorsey Wright & Associates's Merrimack Pharmaceuticals, Inc. position peaked at $24.6K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2023.

Based on Dorsey Wright & Associates's 13F filing for Q4 2023, filed 13 Feb 2024.